February 7, 2019 06:30 PM EST
R&D

Re­searchers spot­light a bas­ket of 'good' re­sponse rates for the next ADC in Seat­tle Ge­net­ic­s' pipeline

Amber Tong

In Au­gust 2017, Seat­tle Ge­net­ics opt­ed in­to a de­vel­op­ment part­ner­ship for an an­ti­body-drug con­ju­gate de­vel­oped by Gen­mab as part of a col­lab­o­ra­tion sev­en years …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Af­ter stock slides, Am­gen ad­dress­es bone den­si­ty talk on obe­si­ty drug

Met­sera rais­es $215M for stud­ies of GLP-1 and amylin obe­si­ty drugs

Adap­ti­m­mune's sec­ond T cell re­cep­tor cell ther­a­py for rare sar­co­mas pass­es piv­otal test

New can­cer class heats up as BioN­Tech buys out Chi­na part­ner and its PD-L1/VEGF drug

J&J takes 340B fight with fed­er­al gov­ern­ment to court

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times